No analyst coverage available for this stock.
Microba Life Sciences Limited is a biotechnology company specializing in precision microbiome science. Its primary mission is to advance human health by leveraging cutting-edge technology for analyzing the human gut microbiome. Microba develops and provides clinical-grade microbiome testing services that are used by researchers, clinicians, and consumers globally, as well as pioneering the discovery and development of novel therapeutics targeting major chronic diseases such as metabolic, autoimmune, and gastrointestinal disorders. A notable feature of Microba is its emphasis on harnessing gut microbiome insights to identify new relationships between microbiota and disease, supporting the development of innovative diagnostic tools and therapeutic solutions. The company is active in forming partnerships with leading organizations within the healthcare and life sciences sectors, expanding its impact across both clinical research and consumer health. Founded in 2017 and headquartered in Brisbane, Microba Life Sciences Limited plays a significant role in the emerging field of microbiome-based biotechnology, contributing to the integration of microbiome data into mainstream healthcare and translational medicine.